001     127371
005     20240228140922.0
024 7 _ |a 10.1007/s00401-015-1454-8
|2 doi
024 7 _ |a pmid:26087904
|2 pmid
024 7 _ |a 0001-6322
|2 ISSN
024 7 _ |a 1432-0533
|2 ISSN
024 7 _ |a altmetric:4281052
|2 altmetric
037 _ _ |a DKFZ-2017-03396
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Reuss, David E
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.
260 _ _ |a Berlin
|c 2015
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1524128127_12550
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a IDH wild type (IDHwt) anaplastic astrocytomas WHO grade III (AA III) are associated with poor outcome. To address the possibilities of molecular subsets among astrocytoma or of diagnostic reclassification, we analyzed a series of 160 adult IDHwt tumors comprising 120 AA III and 40 diffuse astrocytomas WHO grade II (A II) for molecular hallmark alterations and established methylation and copy number profiles. Based on molecular profiles and hallmark alterations the tumors could be grouped into four major sets. 124/160 (78 %) tumors were diagnosed as the molecular equivalent of conventional glioblastoma (GBM), and 15/160 (9 %) as GBM-H3F3A mutated (GBM-H3). 13/160 (8 %) exhibited a distinct methylation profile that was most similar to GBM-H3-K27, however, lacked the H3F3A mutation. This group was enriched for tumors of infratentorial and midline localization and showed a trend towards a more favorable prognosis. All but one of the 120 IDHwt AA III could be assigned to these three groups. 7 tumors recruited from the 40 A II, comprised a variety of molecular signatures and all but one were reclassified into distinct WHO entities of lower grades. Interestingly, TERT mutations were exclusively restricted to the molecular GBM (78 %) and associated with poor clinical outcome. However, the GBM-H3 group lacking TERT mutations appeared to fare even worse. Our data demonstrate that most of the tumors diagnosed as IDHwt astrocytomas can be allocated to other tumor entities on a molecular basis. The diagnosis of IDHwt diffuse astrocytoma or anaplastic astrocytoma should be used with caution.
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Biomarkers, Tumor
|2 NLM Chemicals
650 _ 7 |a Isocitrate Dehydrogenase
|0 EC 1.1.1.41
|2 NLM Chemicals
650 _ 7 |a isocitrate dehydrogenase 2, human
|0 EC 1.1.1.41
|2 NLM Chemicals
650 _ 7 |a IDH1 protein, human
|0 EC 1.1.1.42.
|2 NLM Chemicals
650 _ 7 |a TERT protein, human
|0 EC 2.7.7.49
|2 NLM Chemicals
650 _ 7 |a Telomerase
|0 EC 2.7.7.49
|2 NLM Chemicals
700 1 _ |a Kratz, Annekathrin
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Sahm, Felix
|0 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
|b 2
|u dkfz
700 1 _ |a Capper, David
|0 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c
|b 3
|u dkfz
700 1 _ |a Schrimpf, Daniel
|0 P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc
|b 4
|u dkfz
700 1 _ |a Koelsche, Christian
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Hovestadt, Volker
|0 P:(DE-He78)744146d3b5a3df1e0ac555e5bf1ee5cc
|b 6
|u dkfz
700 1 _ |a Bewerunge-Hudler, Melanie
|0 P:(DE-He78)7999346780553d7fab7ba69d5afdfa71
|b 7
|u dkfz
700 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 8
|u dkfz
700 1 _ |a Schittenhelm, Jens
|b 9
700 1 _ |a Mittelbronn, Michel
|0 P:(DE-He78)3494efbbc54460b109fe9eab0595adda
|b 10
|u dkfz
700 1 _ |a Rushing, Elisabeth
|b 11
700 1 _ |a Simon, Matthias
|b 12
700 1 _ |a Westphal, Manfred
|b 13
700 1 _ |a Unterberg, Andreas
|b 14
700 1 _ |a Platten, Michael
|0 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5
|b 15
|u dkfz
700 1 _ |a Paulus, Werner
|b 16
700 1 _ |a Reifenberger, Guido
|0 P:(DE-HGF)0
|b 17
700 1 _ |a Tonn, Joerg-Christian
|b 18
700 1 _ |a Aldape, Kenneth
|b 19
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 20
|u dkfz
700 1 _ |a Korshunov, Andrey
|0 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
|b 21
|u dkfz
700 1 _ |a Weller, Michael
|b 22
700 1 _ |a Herold-Mende, Christel
|b 23
700 1 _ |a Wick, Wolfgang
|0 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
|b 24
|u dkfz
700 1 _ |a Brandner, Sebastian
|b 25
700 1 _ |a von Deimling, Andreas
|0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
|b 26
|e Last author
|u dkfz
773 _ _ |a 10.1007/s00401-015-1454-8
|g Vol. 130, no. 3, p. 407 - 417
|0 PERI:(DE-600)1458410-4
|n 3
|p 407 - 417
|t Acta neuropathologica
|v 130
|y 2015
|x 1432-0533
909 C O |o oai:inrepo02.dkfz.de:127371
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)744146d3b5a3df1e0ac555e5bf1ee5cc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)7999346780553d7fab7ba69d5afdfa71
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)3494efbbc54460b109fe9eab0595adda
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 26
|6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|2 G:(DE-HGF)POF3-300
|v Translational cancer research
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2015
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA NEUROPATHOL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ACTA NEUROPATHOL : 2015
920 1 _ |0 I:(DE-He78)G380-20160331
|k G380
|l KKE Neuropathologie
|x 0
920 1 _ |0 I:(DE-He78)B060-20160331
|k B060
|l Molekulare Genetik
|x 1
920 1 _ |0 I:(DE-He78)W110-20160331
|k W110
|l Microarray Unit
|x 2
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 3
920 1 _ |0 I:(DE-He78)G160-20160331
|k G160
|l Neuroimmunologie und Hirntumorimmunologie
|x 4
920 1 _ |0 I:(DE-He78)G370-20160331
|k G370
|l KKE Neuroonkologie
|x 5
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 6
920 1 _ |0 I:(DE-He78)L401-20160331
|k L401
|l DKTK Essen
|x 7
920 1 _ |0 I:(DE-He78)L701-20160331
|k L701
|l DKTK München
|x 8
920 1 _ |0 I:(DE-He78)L501-20160331
|k L501
|l DKTK Frankfurt
|x 9
920 1 _ |0 I:(DE-He78)L801-20160331
|k L801
|l DKTK Tübingen
|x 10
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G380-20160331
980 _ _ |a I:(DE-He78)B060-20160331
980 _ _ |a I:(DE-He78)W110-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)G160-20160331
980 _ _ |a I:(DE-He78)G370-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a I:(DE-He78)L401-20160331
980 _ _ |a I:(DE-He78)L701-20160331
980 _ _ |a I:(DE-He78)L501-20160331
980 _ _ |a I:(DE-He78)L801-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21